In a country still reckoning with how medicine should respond to the distress of gender-questioning children, a British high court has allowed a clinical trial of puberty-blocking drugs to proceed at King's College London. Mr Justice Chamberlain found that those seeking to halt the Pathways study had no realistic legal case, clearing the way for more than 220 children aged 11 to 16 to be recruited beginning August 1st. The trial is itself a consequence of reckoning — born from a 2024 review that found gender medicine had been practiced for years on foundations too fragile to trust. What unfold
High Court Clears Path for Puberty Blocker Trial on Children
Children aged 11-16 will participate in a clinical trial involving puberty-blocking drugs, with potential risks and benefits to be studied.
The medical profession and morality do not always walk hand in hand
Mark
Why did the judge think the legal challenge had no realistic chance of success?
Mimi
He focused on the safeguards already in place. Every child would be assessed over months by specialist doctors before enrollment. The judge seemed to think that level of individual scrutiny made the harm argument speculative rather than concrete.
Mark
But the opponents say there isn't enough evidence that puberty blockers actually help these children. Doesn't that matter?
Mimi
It does matter—that's exactly why this trial exists. The Cass review found the evidence base was weak. So now they're trying to build it. The judge essentially said: the safety protocols are sound, so let the research happen.
Mark
Keira Bell took these drugs as a teenager and later detransitioned. Doesn't her experience suggest real harm?
Mimi
Her experience is real and matters to her. But the judge was looking at whether the trial itself—with its specific protections and participant selection—posed an unreasonable risk. One person's outcome isn't the same as evidence about the trial's design.
Mark
What happens if the trial finds puberty blockers don't help, or cause harm?
Mimi
Then the NHS has data it didn't have before. That's the whole point. Right now they're operating in a fog. This trial is meant to clear it.
Mark
Are there children who will be harmed by participating?
Mimi
That's the question no one can answer yet. The trial is designed to find out. The judge decided the design itself—the screening, the monitoring, the eligibility limits—was rigorous enough to justify proceeding.
Le Pouls
- A high court judge rejected a legal challenge to the Pathways trial on Friday, ruling opponents had no realistic prospect of success — clearing the path for recruitment to begin within days.
- Detransitioner Keira Bell and psychotherapist James Esses had argued the trial posed unacceptable risks to minors, and the Bayswater Group warned that basic ethical protections for children had not been properly met.
- The court found that the trial's built-in safeguards — months of specialist assessment and strict eligibility criteria — were sufficient to protect participants from foreseeable harm.
- Bell called the ruling a tragedy, insisting that medicine and morality do not always move together, and that a truly ethical system would have made this trial unthinkable.
- The Pathways trial is a direct answer to the 2024 Cass review, which found that years of puberty blocker prescriptions had rested on dangerously weak evidence — and its results could rewrite NHS treatment protocols for gender-dysphoric youth.
In a country still reckoning with how medicine should respond to the distress of gender-questioning children, a British high court has allowed a clinical trial of puberty-blocking drugs to proceed at King's College London. Mr Justice Chamberlain found that those seeking to halt the Pathways study had no realistic legal case, clearing the way for more than 220 children aged 11 to 16 to be recruited beginning August 1st. The trial is itself a consequence of reckoning — born from a 2024 review that found gender medicine had been practiced for years on foundations too fragile to trust. What unfolds now is an attempt to replace uncertainty with evidence, though for those who carry the deepest doubts, the uncertainty has not yet been resolved.
A British high court judge on Friday cleared the way for a clinical trial of puberty-blocking drugs in children, rejecting a legal challenge from campaigners who argued the research posed unacceptable risks to young participants. Mr Justice Chamberlain ruled that the challengers had no realistic prospect of success, allowing King's College London to begin recruiting more than 220 children aged 11 to 16 from August 1st.
The legal challenge had been brought by psychotherapist James Esses, detransitioner Keira Bell, and the Bayswater Group — an organization supporting parents of gender-questioning children. They argued that the trial's design and the known risks of puberty suppression raised fundamental questions about whether protections for minors had been properly observed. Bell, who took puberty blockers as a teenager before later detransitioning, told the BBC the ruling was a tragedy, saying that medicine and morality do not always align — and that if they did, such a trial would be unthinkable.
The judge's decision rested on the safeguards embedded in the trial's structure. Each child would be assessed over many months by specialist doctors, with enrollment limited to those with long-standing gender incongruence who had already received comprehensive psychological and social support. King's College London noted the trial had been independently reviewed and approved by the HRA and MHRA.
The Pathways trial was conceived in direct response to the 2024 Cass review, which found that gender medicine had been built on remarkably weak evidence. Puberty blockers, originally developed for early-onset puberty, had been prescribed off-label to gender-dysphoric young people until the NHS halted the practice following that review. The trial is designed to generate the clinical data that has long been absent — and its findings could ultimately reshape how the NHS treats gender dysphoria in children.
A British high court judge on Friday cleared the way for a clinical trial of puberty-blocking drugs in children, rejecting a legal challenge mounted by campaigners who argued the research posed unacceptable risks to young participants. Mr Justice Chamberlain ruled that the challengers had failed to make a case with any realistic prospect of success in court. The decision allows King's College London to proceed with the Pathways trial, which will begin recruiting more than 220 children aged 11 to 16 starting August 1st.
The legal fight centered on whether the study met the threshold for ethical research involving minors. Opponents—including psychotherapist James Esses and Keira Bell, a woman who took puberty blockers as a teenager before later detransitioning—had sought to halt the trial on grounds that it could harm participants. The Bayswater Group, an organization supporting parents of gender-questioning children, joined the challenge, contending that the trial's design, scale, and the known risks of the intervention raised fundamental questions about whether protections for minors had been properly implemented.
The judge's reasoning hinged on the safeguards already built into the trial's structure. He noted that each child would undergo assessment over many months by specialist doctors, who would only enroll those with a reasonable prospect of clinical benefit from treatment. King's College London emphasized that eligibility would be strictly limited to young people with long-standing gender incongruence who had already received comprehensive psychological and social support through NHS gender services. The university said the trial design had been independently reviewed and approved by the UK's health research regulators, the HRA and MHRA.
Bell responded to the ruling with dismay, telling the BBC that it was a tragedy the court had refused to allow the challenge to proceed. She argued that medicine and morality do not always align, and that if they did, the trial would be unthinkable. The Bayswater Group maintained its position that the study failed to meet legal and ethical standards, citing the absence of sufficient prior evidence that puberty blockers benefit the children who receive them.
The trial exists in direct response to a 2024 review of gender identity services by Dr. Hilary Cass, which concluded that gender medicine rested on remarkably weak evidence and shaky foundations. Puberty blockers were originally developed to treat early-onset puberty in children. They were later prescribed off-label to young people with gender dysphoria until the NHS halted that practice last year following the Cass review's findings. The Pathways trial is designed to generate the clinical evidence that has long been missing—data on both the potential benefits and risks of puberty suppression in this population. The results, when they come, could reshape how the NHS approaches treatment for gender-dysphoric youth.
Citations marquantes
It's a tragedy that the court has refused permission for this challenge to proceed. The medical profession and morality do not always walk hand in hand.— Keira Bell, detransitioner and trial opponent, to the BBC
The Pathways trial is a carefully designed study to give much needed evidence about the potential benefits and risks of puberty suppression to improve NHS care.— King's College London spokesperson
Envie de l'histoire complète ?
Lire l'original sur The Guardian ↗
Health & Medicine